Skip to main content
Premium Trial:

Request an Annual Quote

NanoString, Bio-Techne to Codevelop, Market Integrated RNA Spatial Profiling Workflow

NEW YORK (GenomeWeb) – Bio-Techne and NanoString Technologies said today that they are partnering to create a workflow for spatial genomics research uniting Bio-Techne's RNAscope reagent portfolio with NanoString's GeoMx RNA assays and digital spatial profiling instrument.

Under the terms of the agreement, NanoString and Bio-Techne will develop, validate, and comarket protocols that combine RNAscope reagents and GeoMx assays. In addition, NanoString will provide RNAscope research services through its GeoMx DSP Technology Access Program.

According to the companies, this combination will be the basis of an ongoing partnership aimed at further integration of their respective platforms. Financial terms of the deal were not disclosed.

Both firms' technologies are being featured in a white paper that they are making available at the American Association of Cancer Research conference beginning this weekend, where NanoString plans to officially launch the GeoMx platform.

In combination, the firms believe the workflow can help researchers extend spatial genomics applications from basic research to translational and clinical applications.

"Understanding the tissue microenvironment at the cellular and system level enables researchers to gain insights into tissue function and mechanisms as related to normal development as well as mechanism of disease," Kim Kelderman, president of the diagnostics and genomics segment at Bio-Techne, said in a statement. "By partnering with NanoString, we believe we can create extremely powerful workflows to accelerate our customers' research," he added.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.